MARKET WIREYahoo • 1d ago
Here's Why CRISPR Therapeutics AG (CRSP) Fell More Than Broader MarketCRISPR Therapeutics AG (CRSP) closed the most recent trading day at $51.36, moving 5.34% from the previous trading session.
Why CRSP Stock advanced +0.28% Today — RQD Quant Desk Flash
$54.26 +0.28% NASDAQ • Public Delayed / 60s Snapshot
CRISPR Therapeutics AG (CRSP) receives a Roarable Rating of D+ (Sell) and flashes a Red SELL / AVOID warning (55/100 RQD Confidence). Our SEC filing scanner spotted paper earnings outpacing real operating cash flow (+61.2% (NI vs OCF)) while unpaid customer invoices grew—a classic sign to step aside until cash flow catches up.
ROARABLE D+ • SELL / AVOID
Cap $5.25B
INTERACTIVE SCENARIO DECK:
RQD QUANT TACHOMETERSELL / AVOID • D+
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
5-PILLAR SNOWFLAKE RADARRw D · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-1.3% Base Target
WHALE OPTIONS TUG-OF-WAR:55% Call Buyers ($2.5M)
45% PutsMax Pain: $53.00
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why CRSP Stock advanced +0.28% Today — RQD Quant Desk Flash
CRISPR Therapeutics AG (CRSP) advanced +0.28% to $54.26 as options desks priced 55% call premium vs. 45% put protection around the $53 max-pain magnet. Accounting Warning: Paper earnings outpaced operating cash flow (+61.2% (NI vs OCF)) as receivables rose.
- ▸Technical Tape: Trading at 49% of its 52-week range ($44.12 – $64.74) with RSI-14 at 47.6 (NEUTRAL RANGE).
- ▸Whale Options Positioning: $2.5M in bullish call flow vs. $2.0M in put flow (Put/Call 0.82x, implied earnings swing ±7.3%).
- ▸Primary SEC / Cross-Feed Trigger: CRSP Accounting Gap: Net Income (-58.8%) Outpaced OCF (-120%) With +90% Working-Capital Build
Live CRSP Headlines & Catalysts
MARKET WIREYahoo • 1d ago
Fidelity’s Health Care ETF Holds the Biotechs XLV Skips. Retirees Should Know the DifferenceTwo health care ETFs track the same sector but own very different slices of it, and for retirees building a portfolio, that gap in biotech exposure and concentration could matter more than the nearly identical returns su
MARKET WIREYahoo • 2d ago
3 Promising Genomics Stocks to Add to Your Portfolio NowGenomics and synthetic biology are transforming healthcare through precision medicine and gene editing, putting ILMN, QURE and TXG in focus as the markets expand.
CATALYSTYahoo • 5d ago
Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards?VRTX is poised for a Q3 earnings beat as strong demand for Trikafta, Alyftrek's growth and rising Casgevy and Journavx sales drive expectations.
MARKET WIREYahoo • 7d ago
Learn Why The Bull Case For CRISPR Therapeutics Stock Could Change Following CFO ChangeCRISPR Therapeutics appointed Andrew J. Silver as Chief Financial Officer and principal financial officer on October 19, 2026, following his tenure as Senior Vice President of Finance and a prior decade in assurance serv
MARKET WIREYahoo • 7d ago
CRISPR Therapeutics (CRSP) Promotes Andrew Silver To CFO As Raju Prasad ResignsCRISPR Therapeutics (NasdaqGM:CRSP) has promoted Andrew J. Silver to Chief Financial Officer, effective October 19, 2026. Outgoing CFO Raju Prasad, Ph.D., has resigned from his role, also effective October 19, 2026. Silv
MARKET WIREYahoo • 7d ago
Forget Casgevy: CRISPR Therapeutics' Heart-Disease Data Could Matter MoreThe company's gene-editing-focused platform looks promising.
MARKET WIREYahoo • 8d ago
CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should KnowIn the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $49.39, marking a -1.2% move from the previous day.
MARKET WIREYahoo • 9d ago
Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to KnowRecently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
CATALYSTYahoo • 9d ago
The Outlook of CRISPR Therapeutics Stock Does Not Look Strong After Its CFO ResignsThe valuation of CRSP stock is high, and its pipeline is not advanced.
🔴 SUNDAY NIGHT PREP • 7:00 PM ETHosted Live by Perry Belcher & Guest Forensic Quant Desk
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring CRSP)
- ✓Live walkthrough of CRSP's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
RQD INSIDER CLUB UPGRADE$49/YEAR
Want Plain-English AI Custom Indicators, Daily Pro Trader Video Clips & SMS Crash Alerts?
CRSP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -1.76%📐 WEDGE COMPRESSION COIL
2026-10-30O $53.27H $54.10L $50.60C $51.42VOL 1.17M
RES: $59.61SUP: $47.56SMA50: $54.19SMA200: $52.88
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
CRSP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
21.4%/yr Implied 5Y Growth
vs. -65.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on CRSP today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for CRSP. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CRSP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
CRSP Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is CRSP stock moving today?
Why CRSP Stock advanced +0.28% Today — RQD Quant Desk Flash. Accounting Warning: Paper earnings outpaced operating cash flow (+61.2% (NI vs OCF)) as receivables rose.